Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2000 2
2001 3
2002 3
2004 4
2005 3
2006 3
2007 3
2008 7
2009 6
2010 2
2011 9
2012 7
2013 5
2014 6
2015 8
2016 9
2017 6
2018 6
2019 11
2020 11
2021 9
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Response letter.
Keyvani K. Keyvani K. Alzheimers Dement. 2017 Sep;13(9):1070-1071. doi: 10.1016/j.jalz.2017.06.003. Epub 2017 Jul 8. Alzheimers Dement. 2017. PMID: 28692820 No abstract available.
[Cerebral amyloid angiopathy and dementia].
Berlit P, Keyvani K, Krämer M, Weber R. Berlit P, et al. Among authors: keyvani k. Nervenarzt. 2015 Oct;86(10):1248-54. doi: 10.1007/s00115-015-4407-5. Nervenarzt. 2015. PMID: 26384105 Review. German.
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. Among authors: keyvani k. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Kebir S, et al. Among authors: keyvani k. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. Clin Cancer Res. 2023. PMID: 36239995 Free PMC article.
[Biopsy diagnosis in neurology].
Koelble K, Herring A, Keyvani K. Koelble K, et al. Among authors: keyvani k. Fortschr Neurol Psychiatr. 2013 Apr;81(4):210-27; quiz 228-9. doi: 10.1055/s-0032-1330526. Epub 2013 Apr 15. Fortschr Neurol Psychiatr. 2013. PMID: 23589114 Review. German. No abstract available.
Regorafenib in patients with recurrent high-grade astrocytoma.
Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M. Kebir S, et al. Among authors: keyvani k. J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28. J Cancer Res Clin Oncol. 2019. PMID: 30820715
Study of angiogenic signaling pathways in hemangioblastoma.
Pierscianek D, Wolf S, Keyvani K, El Hindy N, Stein KP, Sandalcioglu IE, Sure U, Mueller O, Zhu Y. Pierscianek D, et al. Among authors: keyvani k. Neuropathology. 2017 Feb;37(1):3-11. doi: 10.1111/neup.12316. Epub 2016 Jul 7. Neuropathology. 2017. PMID: 27388534
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Schmidt T, et al. Among authors: keyvani k. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37547266 Free PMC article.
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E, Kebir S, Ahmed MS, Keyvani K, Umutlu L, Kanaki T, Zaremba A, Reinboldt-Jockenhoefer F, Knispel S, Gratsias E, Roesch A, Ugurel S, Scheffler B, Schadendorf D, Livingstone E, Meier F, Glas M, Zimmer L. Chorti E, et al. Among authors: keyvani k. Eur J Cancer. 2021 May;148:395-404. doi: 10.1016/j.ejca.2021.02.016. Epub 2021 Mar 28. Eur J Cancer. 2021. PMID: 33789203
115 results